Ulcerative Colitis Treatment
Asana is initially focusing its resources on the development of a therapy for Ulcerative Colitis (UC). Once ECMH is established in UC, other therapies will be developed based on the fundamentals of the platform technology.
Asana believes it will be the first to provide physicians with a first-in-class non-pharmacological, non-surgical treatment option for their patients suffering from Ulcerative Colitis.
Asana’s solution is to leverage Extracellular Matrix (ECM), a mature tissue engineering technology, to the GI space. This technology has been commercialized for over a decade and has been used in many other clinical applications. Asana is confident that this engineered tissue material can be used to create an environment favorable to the growth of new colon lining in ulcerative colitis patients.